CONTEXT: Evidence suggests that chemotherapy-induced neuropathy (CIN) is a significant problem for cancer survivors. However, a detailed phenotypic characterization of CIN in cancer survivors is not available. OBJECTIVES: To evaluate between-group differences in demographic and clinical characteristics, as well as in measures of sensation, function, and postural control, in a sample of cancer survivors who received a platinum and/or a taxane-based CTX regimen and did (n = 426) and did not (n = 197) develop CIN. METHODS: Survivors completed self-report questionnaires and underwent objective testing (i.e., light touch, pain sensation, cold sensation, vibration, muscle strength, grip strength, Purdue Pegboard test, Timed Get Up and Go test, Fullerton Advanced Balance test). Parametric and nonparametric statistics were used to compare between-group differences in study outcomes. RESULTS: Of the 426 survivors with CIN, 4.9% had CIN only in their upper extremities, 27.0% only in their lower extremities, and 68.1% in both their upper and lower extremities. Demographic and clinical characteristics associated with CIN included the following: older age, lower annual income, higher body mass index, a higher level of comorbidity, being born prematurely, receipt of a higher cumulative dose of chemotherapy, and a poorer functional status. Survivors with CIN had worse outcomes for all of the following objective measures: light touch, pain, temperature, vibration, upper and lower extremity function, and balance. CONCLUSIONS: This study is the first to provide a detailed phenotypic characterization of CIN in cancer survivors who received a platinum and/or a taxane compound. These data can serve as a benchmark for future studies of CIN in cancer survivors.
CONTEXT: Evidence suggests that chemotherapy-induced neuropathy (CIN) is a significant problem for cancer survivors. However, a detailed phenotypic characterization of CIN in cancer survivors is not available. OBJECTIVES: To evaluate between-group differences in demographic and clinical characteristics, as well as in measures of sensation, function, and postural control, in a sample of cancer survivors who received a platinum and/or a taxane-based CTX regimen and did (n = 426) and did not (n = 197) develop CIN. METHODS: Survivors completed self-report questionnaires and underwent objective testing (i.e., light touch, pain sensation, cold sensation, vibration, muscle strength, grip strength, Purdue Pegboard test, Timed Get Up and Go test, Fullerton Advanced Balance test). Parametric and nonparametric statistics were used to compare between-group differences in study outcomes. RESULTS: Of the 426 survivors with CIN, 4.9% had CIN only in their upper extremities, 27.0% only in their lower extremities, and 68.1% in both their upper and lower extremities. Demographic and clinical characteristics associated with CIN included the following: older age, lower annual income, higher body mass index, a higher level of comorbidity, being born prematurely, receipt of a higher cumulative dose of chemotherapy, and a poorer functional status. Survivors with CIN had worse outcomes for all of the following objective measures: light touch, pain, temperature, vibration, upper and lower extremity function, and balance. CONCLUSIONS: This study is the first to provide a detailed phenotypic characterization of CIN in cancer survivors who received a platinum and/or a taxane compound. These data can serve as a benchmark for future studies of CIN in cancer survivors.
Authors: Meredith A Wampler; Kimberly S Topp; Christine Miaskowski; Nancy N Byl; Hope S Rugo; Kate Hamel Journal: Arch Phys Med Rehabil Date: 2007-08 Impact factor: 3.966
Authors: Antoinetta J M Beijers; Floortje Mols; Vivianne C G Tjan-Heijnen; Catharina G Faber; Lonneke V van de Poll-Franse; Gerard Vreugdenhil Journal: Acta Oncol Date: 2014-11-24 Impact factor: 4.089
Authors: Mark P Jensen; Arnold R Gammaitoni; David O Olaleye; Napoleon Oleka; Srinivas R Nalamachu; Bradley S Galer Journal: J Pain Date: 2006-11 Impact factor: 5.820
Authors: Christine Miaskowski; Steven M Paul; Judy Mastick; Gary Abrams; Kimberly Topp; Betty Smoot; Kord M Kober; Margaret Chesney; Melissa Mazor; Grace Mausisa; Mark Schumacher; Yvette P Conley; Jennifer Henderson Sabes; Steven Cheung; Margaret Wallhagen; Jon D Levine Journal: J Pain Symptom Manage Date: 2018-03-07 Impact factor: 3.612
Authors: Maria Olsson; Gunnar Steineck; Karin Enskär; Ulrica Wilderäng; Marianne Jarfelt Journal: J Cancer Surviv Date: 2018-03-05 Impact factor: 4.442
Authors: Kord M Kober; Melissa Mazor; Gary Abrams; Adam Olshen; Yvette P Conley; Marilyn Hammer; Mark Schumacher; Margaret Chesney; Betty Smoot; Judy Mastick; Steven M Paul; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2018-08-30 Impact factor: 3.612
Authors: Christine Miaskowski; Steven M Paul; Judy Mastick; Mark Schumacher; Yvette P Conley; Betty Smoot; Gary Abrams; Kord M Kober; Steven Cheung; Jennifer Henderson-Sabes; Margaret Chesney; Melissa Mazor; Margaret Wallhagen; Jon D Levine Journal: Eur J Oncol Nurs Date: 2017-11-07 Impact factor: 2.398
Authors: Scott M Monfort; Xueliang Pan; Robyn Patrick; Bhuvaneswari Ramaswamy; Robert Wesolowski; Michelle J Naughton; Charles L Loprinzi; Ajit M W Chaudhari; Maryam B Lustberg Journal: Breast Cancer Res Treat Date: 2017-04-03 Impact factor: 4.872
Authors: Grace A Kanzawa-Lee; Robert Knoerl; Clare Donohoe; Celia M Bridges; Ellen M Lavoie Smith Journal: Semin Oncol Nurs Date: 2019-04-30 Impact factor: 2.315
Authors: Christine Miaskowski; Judy Mastick; Steven M Paul; Gary Abrams; Steven Cheung; Jennifer Henderson Sabes; Kord M Kober; Mark Schumacher; Yvette P Conley; Kimberly Topp; Betty Smoot; Grace Mausisa; Melissa Mazor; Margaret Wallhagen; Jon D Levine Journal: J Cancer Surviv Date: 2017-11-20 Impact factor: 4.442
Authors: Ilufredo Y Tantoy; Bruce A Cooper; Anand Dhruva; Janine Cataldo; Steven M Paul; Yvette P Conley; Marilyn Hammer; Fay Wright; Laura B Dunn; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2017-10-17 Impact factor: 3.612